Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.55 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | MMP12 | P39900 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13932067 | 1.00 | PARP1 (0.55) | PARP1NR3C2ALDH1A1LMNATRPV1 | |
| SCHEMBL10923540 | 0.86 | PARP1 (0.69) | PARP1NR3C2ALDH1A1MMP12MAPT | |
| SCHEMBL13932097 | 0.84 | ALDH1A1 (0.60) | PARP1NR3C2ALDH1A1LMNATRPV1 | |
| SCHEMBL4263597 | 0.84 | ALDH1A1 (0.60) | PARP1NR3C2ALDH1A1LMNATRPV1 | |
| SCHEMBL13932125 | 0.82 | NR3C2 (0.55) | PARP1NR3C2ALDH1A1LMNATRPV1 | |
| SCHEMBL4266687 | 0.82 | NR3C2 (0.55) | PARP1NR3C2ALDH1A1LMNATRPV1 | |
| SCHEMBL13932129 | 0.81 | NR3C2 (0.62) | PARP1NR3C2ALDH1A1LMNATRPV1 | |
| SCHEMBL4258190 | 0.81 | NR3C2 (0.62) | PARP1NR3C2ALDH1A1LMNATRPV1 | |
| SCHEMBL27751925 | 0.80 | ALDH1A1 (0.65) | PARP1NR3C2ALDH1A1LMNATRPV1 | |
| SCHEMBL13932098 | 0.80 | NR3C2 (0.55) | PARP1NR3C2ALDH1A1LMNATRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054417-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | IRM LLC (BM) | 2009-02-26 | — | — | US | claimed |
| JP-2008508314-A | — | — | 2008-03-21 | — | — | JP | claimed |
| EP-1778242-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | IRM LLC (BM) | 2007-05-02 | — | — | EP | claimed |
| WO-2006015259-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | IRM LLC (BM) | 2006-02-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054417-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | NR5A1, ESRRA, NR3C1 | PARP1 4095/4885NR3C2 7/4885ALDH1A1 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.